Literature DB >> 12390328

The sodium iodide symporter: its pathophysiological and therapeutic implications.

Christine Spitzweg1, John C Morris.   

Abstract

The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates the active transport of iodide in the thyroid gland and a number of extrathyroidal tissues, in particular lactating mammary gland. Because of its crucial role in the ability of thyroid follicular cells to trap iodide, cloning of NIS opened an exciting and extensive new field of thyroid-related research. Cloning and molecular characterization of NIS allowed investigation of its expression and regulation in thyroidal and nonthyroidal tissues, and its potential pathophysiological and therapeutic implications in benign and malignant thyroid disease. In addition to its key function in thyroid physiology, NIS-mediated iodide accumulation allows diagnostic thyroid scintigraphy as well as effective therapeutic application of radioiodine in benign and malignant thyroid disease. Characterization and application of NIS as a novel therapeutic gene and the presence of high native NIS expression in the majority of breast cancers further suggest a promising role of NIS in diagnosis and therapy of cancer outside the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390328     DOI: 10.1046/j.1365-2265.2002.01640.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  42 in total

Review 1.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

2.  Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.

Authors:  Weiwei Cheng; Rengyun Liu; Guangwu Zhu; Hui Wang; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

3.  Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.

Authors:  Kathrin Klutz; Michael J Willhauck; Nathalie Wunderlich; Christian Zach; Martina Anton; Reingard Senekowitsch-Schmidtke; Burkhard Göke; Christine Spitzweg
Journal:  Hum Gene Ther       Date:  2011-06-28       Impact factor: 5.695

Review 4.  Standard and emerging therapies for metastatic differentiated thyroid cancer.

Authors:  Christine J O'Neill; Jennifer Oucharek; Diana Learoyd; Stan B Sidhu
Journal:  Oncologist       Date:  2010-02-08

5.  Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter.

Authors:  R Huang; Z Zhao; X Ma; S Li; R Gong; A Kuang
Journal:  Cancer Gene Ther       Date:  2010-10-29       Impact factor: 5.987

Review 6.  [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].

Authors:  C Spitzweg
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

Review 7.  Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Authors:  Sujata Narayanan; A Dimitrios Colevas
Journal:  Curr Treat Options Oncol       Date:  2016-06

8.  TRPM7 is regulated by halides through its kinase domain.

Authors:  Haijie Yu; Zheng Zhang; Annette Lis; Reinhold Penner; Andrea Fleig
Journal:  Cell Mol Life Sci       Date:  2013-03-08       Impact factor: 9.261

9.  Association between sodium iodide symporter and differentiated Thyroid cancer: a meta-analysis of 9 studies.

Authors:  Rui Zhang; Huanjun Wang; Junyu Zhao; Jinming Yao; Hongxia Shang; Huangao Zhu; Lin Liao; Jianjun Dong
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection.

Authors:  Rabea Hinkel; Chiraz El-Aouni; Tonia Olson; Jan Horstkotte; Stefan Mayer; Sebastian Müller; Michael Willhauck; Christine Spitzweg; Franz-Josef Gildehaus; Wolfgang Münzing; Ewald Hannappel; Ildiko Bock-Marquette; J Michael DiMaio; Antonis K Hatzopoulos; Peter Boekstegers; Christian Kupatt
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.